Negara: Amerika Serikat
Bahasa: Inggris
Sumber: NLM (National Library of Medicine)
BUTORPHANOL TARTRATE (UNII: 2L7I72RUHN) (BUTORPHANOL - UNII:QV897JC36D)
Zoetis Inc.
BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE 10 mg in 1 mL
INTRAVENOUS
PRESCRIPTION
TORBUGESIC (butorphanol tartrate injection) is indicated for the relief of pain associated with colic in adult horses and yearlings. Clinical studies in the horse have shown that TORBUGESIC alleviates abdominal pain associated with torsion, impaction, intussusception, spasmodic and tympanic colic and postpartum pain.
50 mL vials TORBUGESIC (butorphanol tartrate injection) Veterinary Injection, 10 mg base activity per mL. 10 mL vials TORBUGESIC (butorphanol tartrate injection) Veterinary Injection, 10 mg base activity per mL. Store at controlled room temperature 20°-25°C (68°-77°F) with excursions between 15°-30°C (59°-86°F).
New Animal Drug Application
TORBUGESIC- BUTORPHANOL TARTRATE SOLUTION ZOETIS INC. ---------- TORBUGES IC (BUTORPHANOL TARTRATE INJECTION) Torbugesic® (butorphanol tartrate injection) CAUTION Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION TORBUGESIC (butorphanol tartrate injection) is a totally synthetic, centrally acting, narcotic agonist- antagonist analgesic with potent antitussive activity. It is a member of the phenanthrene series. The chemical name is Morphinan-3, 14-diol, 17-(cyclobutylmethyl)-, (-)-, (S- (R*, R*))-2,3- dihydroxybutanedioate (1:1) (salt). It is a white, crystalline, water soluble substance having a molecular weight of 477.55; its molecular formula is C21H29NO2•C4H6O6. CHEMICAL STRUCTURE Each mL of TORBUGESIC contains 10 mg butorphanol base (as butorphanol tartrate), 3.3 mg citric acid, USP, 6.4 mg sodium citrate, 4.7 mg sodium chloride, and 0.1 mg benzethonium chloride, q.s. with water for injection. CLINICAL PHARMACOLOGY COMPARATIVE PHARMACOLOGY In animals, butorphanol has been demonstrated to be 4 to 30 times more potent than morphine and pentazocine (Talwin -V) respectively. In humans, butorphanol has been shown to have 5 to 7 times the analgesic activity of morphine and 20 times that of pentazocine. ® ® 1 2,3 Butorphanol has 15 to 20 times the oral antitussive activity of codeine or dextromethorphan in dogs and guinea pigs. As an antagonist, butorphanol is approximately equivalent to nalorphine and 30 times more potent than pentazocine. Cardiopulmonary depressant effects are minimal after treatment with butorphanol as demonstrated in dogs , humans and horses. Unlike classical narcotic agonist analgesics which are associated with decreases in blood pressure, reduction in heart rate and concomitant release of histamine, butorphanol does not cause histamine release. Furthermore, the cardiopulmonary effects of butorphanol are not distinctly dosage-related but rather reach a ceiling effect beyond which further dosage increases result in relatively lesser eff Baca dokumen lengkapnya